The PACS Group, Inc. (NYSE: PACS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret them. As a healthcare holding company in the post-acute care and medical care facilities space, PACS uses SEC reports to describe its facility portfolio, credit arrangements, governance, and risk profile.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of PACS Group’s operations, financial condition, and risk factors. These filings also provide context on the company’s role as a holding company, the structure of its independent operating subsidiaries, and the separation between licensed healthcare providers and non-provider entities. AI-generated highlights can point out key sections on post-acute care operations, use of credit facilities, and lease obligations.
Current reports on Form 8-K are particularly important for PACS, given its history of restatements, credit agreement amendments, and NYSE listing updates. Recent 8-K filings have addressed topics such as forbearance and amendments under the company’s amended and restated credit agreement, events of default and related waivers, NYSE listing extensions tied to delayed SEC filings, and the completion of an independent Audit Committee investigation and related restatements. AI summaries can help users quickly understand the implications of these events.
Users can also access proxy materials such as the Definitive Proxy Statement on Schedule 14A, which outlines matters presented to stockholders at the annual meeting, including director elections, auditor ratification, and advisory votes on executive compensation. In addition, the filings page provides real-time updates from EDGAR and convenient access to other forms, such as notifications of late filings on Form 12b-25. Together, these documents offer a comprehensive view of PACS Group’s regulatory history, governance decisions, and financial reporting, with AI tools available to simplify and explain complex disclosures.
Mark Hancock reported multiple sales of Common stock of PACS via Form 144, listing specific transactions between 06/15/2026 and 07/08/2026. The filing lists individual trades with share counts and gross proceeds, including notable sales of 153,254 shares for $5,568,759.95 and 142,163 shares for $6,444,860.09.
The notice names Citigroup Global Markets Inc. as the broker and records multiple cash sales on discrete dates. The filing is a resale disclosure of transactions by a single holder; cash‑flow treatment and any post‑transaction holdings are not stated in the provided excerpt.
PACS reported proposed sales under Rule 144 via a Form 144 notice. The filing lists an issuer-origin acquisition of 54,626,199 shares on 03/01/2023 and multiple sales by Mark Hancock between 06/15/2026 and 07/06/2026, with individual transactions and cash amounts shown. The notice identifies Citigroup Global Markets Inc as the broker and NYSE as the market.
PACS Group, Inc. Chief Accounting Officer Michelle Renee Lewis reported selling a total of 15,000 shares of common stock in three open-market transactions at weighted average prices around $45 per share. These sales were made pursuant to a Rule 10b5-1 trading plan adopted on March 3, 2026, and she continues to hold 355,338 shares directly after the transactions.
PACS Group director and ten percent owner Mark Hancock reported a mix of stock sales and a new equity award. On July 6, 2026, he sold 142,163 shares of common stock at a weighted average price of $45.3343 per share. He also sold 12,825 shares on July 2, 2026 at $45.0129 and 6,080 shares on July 1, 2026 at $45.0191, all as open-market transactions under a pre-arranged Rule 10b5-1 trading plan.
Following these trades, Hancock directly held 53,945,816 shares of PACS Group common stock. Separately, on July 1, 2026 he received 4,287 restricted stock units, each convertible into one share of common stock, vesting 100% on the earlier of July 1, 2027 or the next annual meeting, subject to his continued service.
PACS Group, Inc. director Patrick Hugh Conway reported receiving an equity award in the form of 4,287 restricted stock units of Common Stock. These RSUs carry no purchase price and increase his direct holdings to 12,444 shares after the award.
The footnote explains that each RSU will convert into one share of Common Stock upon vesting. All RSUs vest on the earlier of July 1, 2027 or the company’s next annual meeting after the grant date, as long as Conway continues to serve the company through that time.
PACS Group, Inc. director Jacqueline Millard received an equity grant in the form of restricted stock units. She acquired 4,287 RSUs, each convertible into one share of common stock upon vesting, at no cash purchase price. After this grant, she holds 20,217 shares of common stock directly. The RSUs will vest 100% on the earlier of July 1, 2027 or the next annual meeting following the grant date, if she continues serving the company.
PACS Group, Inc. reported that director Taylor S. Leavitt received a grant of 4,287 restricted stock units (RSUs), with no cash paid per share. Each RSU will convert into one share of common stock when it vests.
According to the terms, 100% of the RSUs vest on the earlier of July 1, 2027 or the date of the next annual meeting following the grant, as long as Leavitt continues serving the company. After this award, Leavitt holds 19,784 shares of common stock directly.
Dilsaver Evelyn S reported acquisition or exercise transactions in this Form 4 filing.
PACS Group, Inc. director Evelyn S. Dilsaver received an equity award in the form of 4,287 shares of Common Stock as a grant, reported at a price of $0.00 per share, indicating compensation rather than a market purchase. This award is structured as restricted stock units (RSUs), each convertible into one share of Common Stock upon vesting. All of the RSUs will vest on the earlier of July 1, 2027 or the date of the next annual meeting following the grant, assuming she continues to serve the company. After this grant, her directly held position reported in this filing is 36,085 shares of Common Stock.
Mark Hancock reported multiple sales of Common stock of PACS under a Form 144 filing. The filing lists several dispositions between 06/15/2026 and 07/02/2026, including transactions of 153,254 shares on 06/15/2026 and 138,069 shares on 06/25/2026.
The sales list per‑trade proceeds in dollars alongside share counts and identify Citigroup Global Markets Inc at 388 Greenwich Street as the broker. The filing also shows an earlier block of 54,626,199 shares described as "shares acquired at formation of the issuer" dated 03/01/2023.
Mark Hancock reported multiple proposed sales of common stock under a Form 144. The filing lists discrete transactions on 06/15/2026, 06/16/2026, 06/17/2026, 06/25/2026, 06/26/2026, and 07/01/2026 with individual share counts and sale proceeds shown. The transactions are reported as sales of issuer common stock.